Core Viewpoint - Kaskela Law LLC is investigating MaxLinear, Inc. on behalf of the company's long-term investors due to potential violations of securities laws or breaches of fiduciary duties by the company's officers and directors [1][2]. Company Performance - Year to date, shares of MaxLinear's stock have decreased by 25%, currently trading at approximately $15.00 per share [2]. Legal Investigation - The investigation aims to determine if there were any legal violations related to recent corporate actions taken by MaxLinear [2]. - Shareholders of MaxLinear are encouraged to contact Kaskela Law LLC for more information regarding their legal rights and options [3]. Contact Information - Kaskela Law LLC provides contact details for shareholders seeking further information, including phone numbers and a website link [3][4].

PHILADELPHIA , July 10, 2025 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating First American Financial Corp. (NYSE: FAF) ("First American") on behalf of the company's long-term investors. Since November 2024, shares of the company's stock have declined from a trading price of over $70.00 per share to a current trading price of under $62.00, a decline of over 11% in value. The investigation seeks to determine whether First American and/or the company's officers and directors violated the se ...

Core Viewpoint - The article discusses a class action lawsuit against Sarepta Therapeutics, alleging violations of the Securities Exchange Act of 1934 due to misleading statements regarding the safety and efficacy of its gene therapy product, ELEVIDYS, during a specified class period [1][3]. Company Overview - Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on developing therapies for Duchenne muscular dystrophy, including the gene therapy ELEVIDYS [2]. Allegations of the Lawsuit - The lawsuit claims that Sarepta and its executives made false or misleading statements about ELEVIDYS, including significant safety risks, failure to detect severe side effects, and the potential for halting clinical trials due to adverse events [3]. - Specific incidents cited include: - On March 18, 2025, a patient treated with ELEVIDYS suffered acute liver failure leading to death, causing Sarepta's stock to drop over 27% [4]. - On April 4, 2025, Sarepta disclosed that EU authorities requested a review of the death, leading to a further stock decline of over 7% [5]. - On June 15, 2025, a second patient died from acute liver failure, prompting Sarepta to suspend shipments and pause dosing, resulting in a stock drop of over 42% [6]. - On June 24, 2025, the FDA announced an investigation into the risk of acute liver failure associated with ELEVIDYS, causing an additional stock decline of over 8% [7]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Sarepta securities during the class period to seek appointment as lead plaintiff in the lawsuit, representing the interests of all class members [8].

Core Viewpoint - A class action lawsuit has been filed against iRobot Corporation for allegedly making false and misleading statements regarding its financial stability and restructuring plan during the Class Period from January 29, 2024, to March 11, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that iRobot overstated the effectiveness of its Restructuring Plan following the termination of the Amazon Acquisition, leading to doubts about its ability to operate profitably as a standalone company [5]. - It is alleged that the defendants' public statements were materially false and misleading, which resulted in investor damages when the true information became public [5]. Group 2: Participation Information - Investors who purchased iRobot securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm for more information [3][6]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - The Centene class action lawsuit alleges that Centene Corporation and its executives misled investors regarding the company's revenue outlook and growth potential during the specified class period, leading to significant financial losses for shareholders [1][3][4]. Group 1: Lawsuit Details - The class action lawsuit is titled Lunstrum v. Centene Corporation and covers the period from December 12, 2024, to June 30, 2025 [1]. - The lawsuit claims that Centene provided false information about its projected revenue and growth, particularly regarding enrollment rates and morbidity [3]. - On July 1, 2025, Centene withdrew its 2025 guidance, revealing that its market growth across 22 states was lower than expected, resulting in a significant stock price drop of over 40% [4]. Group 2: Financial Impact - The preliminary analysis indicated that over two-thirds of Centene's marketplace share showed lower-than-anticipated enrollment and increased morbidity, contradicting the company's optimistic reports [3]. - Following the withdrawal of guidance, Centene's adjusted diluted EPS was reduced to approximately $2.75, with a total guidance reduction to about $1.8 billion [4]. Group 3: Legal Process - Investors who suffered losses during the class period can seek to become the lead plaintiff in the lawsuit, representing the interests of all class members [5]. - The lead plaintiff has the authority to select a law firm for litigation and does not need to be the lead plaintiff to share in any potential recovery [5]. Group 4: Law Firm Background - Robbins Geller Rudman & Dowd LLP is a prominent law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [6]. - The firm has been recognized for securing significant monetary relief for investors and has a strong track record in handling large securities class action recoveries [6].

Core Viewpoint - A class action lawsuit has been filed against iRobot Corporation for alleged violations of federal securities laws during the specified class period [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased iRobot securities between January 29, 2024, and March 11, 2025 [2]. - The complaint alleges that iRobot made materially false and misleading statements regarding its business operations and prospects, particularly concerning the impact of its Restructuring Plan and the termination of the Amazon Acquisition [3]. Group 2: Allegations Against iRobot - The complaint claims that iRobot overstated the effectiveness of its Restructuring Plan in maintaining stability post-Amazon Acquisition [3]. - It is alleged that iRobot is unlikely to operate profitably as a standalone company, raising doubts about its ability to continue as a going concern [3]. - The public statements made by iRobot's executives are claimed to be materially false and misleading throughout the class period [3]. Group 3: Next Steps for Investors - Investors who suffered losses in iRobot have until September 5, 2025, to request to be appointed as lead plaintiff in the case [4]. - A copy of the complaint can be reviewed on the law firm's website [4]. Group 4: Legal Representation - The law firm representing the investors operates on a contingency fee basis, meaning they will only collect fees if the case is successful [5]. - Bronstein, Gewirtz & Grossman, LLC has a history of recovering substantial amounts for investors in securities fraud cases [6].

Group 1 - Halper Sadeh LLC is investigating CARGO Therapeutics, Inc. for potential violations of federal securities laws related to its sale to Concentra Biosciences, LLC, which is proposed at $4.379 in cash per share plus a contingent value right [1] - WNS (Holdings) Limited is also under investigation for its sale to Capgemini at $76.50 per share [2] - The firm may seek increased consideration for shareholders and additional disclosures regarding the proposed transactions [3] Group 2 - Shareholders are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options without any out-of-pocket payment for legal fees [4] - Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, recovering millions for defrauded investors [4]

Core Viewpoint - A class action lawsuit has been filed against Organon & Co. for alleged violations of the Securities Exchange Act of 1934, claiming misleading statements regarding the company's financial health and projections during the Class Period from November 3, 2022, to April 30, 2025 [1][4]. Company Overview - Organon develops and delivers health solutions through prescription therapies and medical devices [3]. Allegations of the Lawsuit - The lawsuit alleges that Organon misrepresented the risk of loss of exclusivity and price erosion for its product Nexplanon, leading to inflated sales growth expectations that would not reach $1 billion by the end of fiscal year 2025 [4]. - It is claimed that Organon was not on track to achieve a $1 billion milestone payment from Merck & Co. related to Nexplanon sales, nor maintain the required $1 billion in free cash flow to sustain its dividend [4]. - The lawsuit further asserts that Organon might not maintain its corporate debt ratings and lacked a reasonable basis for reporting its business metrics and financial projections during the Class Period [4]. Financial Impact - Following the announcement of its first quarter 2025 financial results, Organon reduced its dividend by 90%, from $1.16 per share annually to $0.08 per share annually, which resulted in a stock price drop of over 27% [5].

Core Viewpoint - Iovance Biotherapeutics Inc. is undergoing a leadership transition with the resignation of CFO Jean-Marc Bellemin amid commercial challenges and a class-action lawsuit related to its flagship drug Amtagvi [1][2][3]. Group 1: Leadership Transition - CFO Jean-Marc Bellemin will resign effective July 10, 2025, to pursue other endeavors, having held the position since November 2020 [1][2]. - The company has not yet named a successor for the CFO role, creating uncertainty during a challenging period [2]. Group 2: Commercial Challenges - Iovance's first-quarter sales for Amtagvi significantly underperformed expectations, leading to a downward revision of full-year revenue projections [3]. - The company's stock price fell over 44%, from $3.17 on May 8, 2025, to $1.75 by the close of trading on May 9, 2025, reflecting investor concerns about commercial execution [7]. Group 3: Legal Issues - Iovance is facing a class-action lawsuit alleging securities fraud related to the company's portrayal of its authorized treatment centers (ATCs) and their role in driving demand for Amtagvi [4][5]. - The lawsuit claims that ATCs experienced delays in initiating treatments and inefficiencies in patient selection, leading to higher patient drop-off rates [5][6]. - Hagens Berman is investigating the allegations to determine if the company's public statements were consistent with internal realities [8].

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between April 29, 2025, and June 23, 2025 [1][2] Group 1: Allegations and Impact - The lawsuit claims that Hims was involved in the deceptive promotion and sale of illegitimate versions of Wegovy®, which posed risks to patient safety [2] - It is alleged that this situation created a substantial risk of termination of Hims' collaboration with Novo Nordisk [2] - The defendants' positive statements regarding the Company's business and prospects are claimed to be materially misleading and lacking a reasonable basis [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until August 25, 2025, to request appointment as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4]